相似文献
1
Burden of Clostridium difficile on the healthcare system.
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S88-92. doi: 10.1093/cid/cis335.
2
Epidemiology of Clostridium difficile infection.
J Pharm Pract. 2013 Oct;26(5):464-75. doi: 10.1177/0897190013499521.
3
Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
J Infect Chemother. 2018 Nov;24(11):892-901. doi: 10.1016/j.jiac.2018.07.020. Epub 2018 Sep 3.
4
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Clin Infect Dis. 2018 Apr 17;66(9):1326-1332. doi: 10.1093/cid/cix1021.
5
Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study.
Infection. 2020 Feb;48(1):129-132. doi: 10.1007/s15010-019-01368-5. Epub 2019 Nov 1.
6
A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
Infect Control Hosp Epidemiol. 2017 Feb;38(2):196-202. doi: 10.1017/ice.2016.246. Epub 2016 Nov 7.
7
Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016.
J Hosp Infect. 2019 Jun;102(2):135-140. doi: 10.1016/j.jhin.2019.01.020. Epub 2019 Jan 25.
8
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.
J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.
9
Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.
BMC Infect Dis. 2016 Jun 18;16:303. doi: 10.1186/s12879-016-1610-3.
10
Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.
BMC Infect Dis. 2016 Aug 25;16(1):447. doi: 10.1186/s12879-016-1786-6.
引用本文的文献
1
Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection.
JAMA Netw Open. 2025 Aug 1;8(8):e2525252. doi: 10.1001/jamanetworkopen.2025.25252.
2
The Pxp Complex Detoxifies 5-Oxoproline and Promotes the Growth of Clostridioides difficile.
Mol Microbiol. 2025 Jul;124(1):66-76. doi: 10.1111/mmi.15373. Epub 2025 May 8.
3
Three stages of laboratory stewardship in improving appropriate testing in a community-based setting.
Antimicrob Steward Healthc Epidemiol. 2025 Mar 19;5(1):e81. doi: 10.1017/ash.2025.55. eCollection 2025.
4
Epidemiologic profile of community-acquired infections: a systematic review and meta-analysis.
Epidemiol Infect. 2025 Mar 4;153:e46. doi: 10.1017/S0950268825000202.
5
Causal role of the gut microbiome in certain human diseases: a narrative review.
eGastroenterology. 2024 Sep 10;2(3):e100086. doi: 10.1136/egastro-2024-100086. eCollection 2024 Sep.
6
Polysaccharide lyase PL3.3 possibly potentiating Clostridioides difficile clinical symptoms based on complete genome analysis of RT046/ST35 and RT012/ST54.
Int Microbiol. 2025 Jan 20. doi: 10.1007/s10123-025-00634-x.
7
Comparative effectiveness of treatments for recurrent infection: a network meta-analysis of randomized controlled trials.
Front Pharmacol. 2024 Oct 17;15:1430724. doi: 10.3389/fphar.2024.1430724. eCollection 2024.
8
Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.
J Infect Dis. 2025 Mar 17;231(3):e511-e520. doi: 10.1093/infdis/jiae466.
9
Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review.
Front Immunol. 2024 Sep 26;15:1439176. doi: 10.3389/fimmu.2024.1439176. eCollection 2024.
10
Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent infection.
mSphere. 2024 Oct 29;9(10):e0070624. doi: 10.1128/msphere.00706-24. Epub 2024 Oct 8.
本文引用的文献
1
Fidaxomicin versus vancomycin for Clostridium difficile infection.
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
2
Matching methods for causal inference: A review and a look forward.
Stat Sci. 2010 Feb 1;25(1):1-21. doi: 10.1214/09-STS313.
3
Multicenter study of Clostridium difficile infection rates from 2000 to 2006.
Infect Control Hosp Epidemiol. 2010 Oct;31(10):1030-7. doi: 10.1086/656245.
4
Older patients in the emergency department: a review.
Ann Emerg Med. 2010 Sep;56(3):261-9. doi: 10.1016/j.annemergmed.2010.04.015.
5
Potentially preventable emergency department visits by nursing home residents: United States, 2004.
NCHS Data Brief. 2010 Apr(33):1-8.
6
Development of a tool for prediction of falls in rehabilitation settings (Predict_FIRST): a prospective cohort study.
J Rehabil Med. 2010 May;42(5):482-8. doi: 10.2340/16501977-0550.
7
Economic healthcare costs of Clostridium difficile infection: a systematic review.
J Hosp Infect. 2010 Apr;74(4):309-18. doi: 10.1016/j.jhin.2009.10.016. Epub 2010 Feb 12.
8
Treatment with monoclonal antibodies against Clostridium difficile toxins.
N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.
9
The National Nursing Home Survey: 2004 overview.
Vital Health Stat 13. 2009 Jun(167):1-155.
10
Understanding the prevalence of inpatient falls associated with toileting in adult acute care settings.
J Nurs Care Qual. 2010 Jan-Mar;25(1):22-30. doi: 10.1097/NCQ.0b013e3181afa321.
Zotero 插件